Tumor lysis syndrome following sorafenib treatment in hepatocellular carcinoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Sorafenib is indicated for the treatment of advanced hepatocellular carcinoma (HCC), but although rare, tumor lysis syndrome (TLS) can be fatal in HCC patients with a large tumor burden. The authors describe the case of a 55-year-old hepatitis B carrier who visited our clinic with progressive dyspnea for 3 weeks. Chest and abdominal computed tomography revealed a huge HCC in the left lobe of the liver with invasion of the inferior vena cava, right atrium, and pulmonary arteries. After 8 days of sorafenib administration, TLS was diagnosed based on the characteristic findings of hyperuricemia, hyperkalemia, and acute kidney injury with massive tumor necrosis by follow-up imaging. Despite discontinuation of sorafenib and supportive care, the patient’s clinical course rapidly deteriorated. The authors describe a rare but fatal complication that occurred soon after sorafenib initiation for HCC. Careful follow-up is required after commencing sorafenib therapy for the early diagnosis and management of TLS.
Abstract
Sorafenib is indicated for the treatment of advanced hepatocellular carcinoma (HCC), but although rare, tumor lysis syndrome (TLS) can be fatal in HCC patients with a large tumor burden. The authors describe the case of a 55-year-old hepatitis B carrier who visited our clinic with progressive dyspnea for 3 weeks. Chest and abdominal computed tomography revealed a huge HCC in the left lobe of the liver with invasion of the inferior vena cava, right atrium, and pulmonary arteries. After 8 days of sorafenib administration, TLS was diagnosed based on the characteristic findings of hyperuricemia, hyperkalemia, and acute kidney injury with massive tumor necrosis by follow-up imaging. Despite discontinuation of sorafenib and supportive care, the patient’s clinical course rapidly deteriorated. The authors describe a rare but fatal complication that occurred soon after sorafenib initiation for HCC. Careful follow-up is required after commencing sorafenib therapy for the early diagnosis and management of TLS.
참고문헌 (10)
- Cairo MS, "Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus", Br J Haematol, 149, pp.578~586 (2010)
- Howard SC, "The tumor lysis syndrome", N Engl J Med, 364, pp.1844~1854 (2011)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Hsieh PM, "Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma:case reports and literature review", World J Gastroenterol, 15, pp.4726~4728 (2009)
- Lehner SG, "Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma", AJR Am J Roentgenol, 185, pp.1307~1309 (2005)
- Huang WS, "Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient", World J Gastroenterol, 15, pp.4464~4466 (2009)
- Joshita S, "A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome", Intern Med, 49, pp.991~994 (2010)
- Shiozawa K, "Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report", Hepatogastroenterology, 57, pp.688~690 (2010)
- Cairo MS, "Tumour lysis syndrome: new therapeutic strategies and classification", Br J Haematol, 127, pp.3~11 (2004)
- Nicholaou T, "Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate", Lancet, 369, pp.1923~1924 (2007)